Handling Worker and Third-Party Exposures to Nanotherapeutics During Clinical Trials
Article first published online: 3 JAN 2013
© 2012 American Society of Law, Medicine & Ethics, Inc.
The Journal of Law, Medicine & Ethics
Special Issue: SYMPOSIUM 1: Nanodiagnostics and Nanotherapeutics: Building Research Ethics and Oversight
Volume 40, Issue 4, pages 856–864, Winter 2012
How to Cite
Ramachandran, G., Howard, J., Maynard, A. and Philbert, M. (2012), Handling Worker and Third-Party Exposures to Nanotherapeutics During Clinical Trials. The Journal of Law, Medicine & Ethics, 40: 856–864. doi: 10.1111/j.1748-720X.2012.00714.x
- Issue published online: 3 JAN 2013
- Article first published online: 3 JAN 2013
The article focuses on issues relating to occupational exposures of researchers and lab workers, and exposures of bystanders such as health care workers and family members during HSR using nanomaterials. Such third-party exposures give rise to unique challenges relating to oversight as well as exposures to worker groups not previously studied. Given the current state of knowledge regarding health risks from such exposures, a more precautionary approach to oversight seems advisable.